TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17586417
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg/HCTZ 12.5 mg
Study: 17586417
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg/HCTZ (stage 2 hypertension)
Study: 17586417
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg/HCTZ (stage 2 hypertension)
Study: 17586417
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg/HCTZ (stage 1 hypertension)
Study: 15556954
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (manipulation followed by exercise)
Study: 11162286
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with indomethacin
Study: 7900078
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 5000 IU
Study: 7900078
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg body weight (mean 75 mg)
Study: 7900078
Drug: Enoxaparin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (high dose)
Study: 2839439
Drug: Concurrent Platinum
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Platinum (DDP) Etoposide (VP‐16) chemotherapy and twice‐daily, 150 cGy radiotherapy to a total dose of 4500 cGy in 3 weeks.
Study: 21974760
Drug: Valsartan/HCTZ 160/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/HCTZ 160/12.5 mg, titrated to 320/25 mg at week 4
Study: 21974760
Drug: Amlodipine/HCTZ (HCTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/HCTZ (HCTZ 12.5 mg monotherapy, then amlodipine 5 mg at week 8 and 10 mg at week 12)
Study: 18381905
Drug: DMXB-A (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMXB-A (higher dose)
Study: 18381905
Drug: DMXB-A (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMXB-A (first treatment arm)
Study: 17532523
Drug: Resiquimod 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resiquimod 0.01 mg/kg
Study: 17532523
Drug: Resiquimod 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resiquimod 0.02 mg/kg
Study: 9450162
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (300 mg, Orfiril long) after fasting
Study: 9450162
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (300 mg, Orfiril long) after a high energy high fat breakfast
Study: 8192698
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg sustained-release theophylline (Bronchoretard) administered in a fasting state
Study: 8192698
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg sustained-release theophylline (Bronchoretard) administered after a standard meal
Study: 8192698
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg sustained-release theophylline (Bronchoretard) administered after a high-caloric fat evening meal
Study: 30306604
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg l-selenomethionine daily for 6 months
Study: 28114798
Drug: Intermittent metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent metoclopramide infusion (10 mg every 6 h)
Study: 28114798
Drug: Continuous metoclopramide
Normalized name: metoclopramide Extended Release Oral Tablet [Gastrobid Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous metoclopramide infusion (2 mg/h)
Study: 26541435
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.5 or 2.0 mg monthly or as needed
Study: 24687826
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg per day for 10 weeks
Study: 24687826
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg per day (4 weeks on, 2 weeks off, 4 weeks on) for 10 weeks
Study: 23294071
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (500 mg)
Study: 19297565
Drug: Annual screening
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual screening with PSA testing and digital rectal examination
Study: 17968163
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no further adjuvant treatment)
Study: 9670578
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (Amoxycillin, Clarithromycin, Omeprazole) for 6 days
Study: 9670578
Drug: Monotherapy (Omeprazole)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (Omeprazole) for 6 weeks
Study: 9670578
Drug: Monotherapy (Omeprazole)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (Omeprazole)
Study: 2452456
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g GVG per day for 3 months
Study: 2452456
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g GVG per day for 3 months
Study: 2452456
Drug: GVG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVG treatment
Study: 25843270
Drug: Licensed inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed inactivated trivalent influenza vaccine (IIV3)
Study: 21059888
Drug: Apratastat (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apratastat (oral administration, single or multiple doses, twice daily)
Study: 19350334
Drug: Knee Outcome
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee Outcome Survey-Activities of Daily Living Scale (KOS-ADLS) questionnaire completed twice a week for test-retest reliability (Group 1)
Study: 19350334
Drug: Knee Outcome
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee Outcome Survey-Activities of Daily Living Scale (KOS-ADLS) questionnaire with additional tests for validity (Group 2)
Study: 7902637
Drug: Vecuronium (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.04 mg.kg‐1)
Study: 7902637
Drug: Atracurium (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.2 mg.kg‐1)
Study: 3026106
Drug: RIT 4237
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT 4237 vaccine alone
Study: 3026106
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of polio and RIT 4237 vaccines
Study: 24950747
Drug: GSK561679 (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK561679 (350 mg nightly for six weeks)
Study: 10859040
Drug: Gavestinel (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gavestinel (800 mg loading dose followed by 200 mg every 12 h for five doses)
Study: 1397742
Drug: Intravenous omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous omeprazole, 40 mg i.v. bolus twice daily for up to 5 days
Study: 1397742
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ranitidine, 400 mg daily for the same time period
Study: 1397742
Drug: Intravenous omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous omeprazole, 40 mg twice daily
Study: 1397742
Drug: Intravenous omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous omeprazole, 40 mg three times daily
Study: 4010475
Drug: 14 gm
Normalized name: Coconut Oil 14 GM/1 DOSE Oral Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 gm choline and 0.35 mg scopolamine (Ch‐Sc)
Study: 30395147
Drug: Eating as
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eating as Treatment (EAT)
Study: 25758100
Drug: Type 2
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 2 implant placement
Study: 25758100
Drug: Both Type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Type 1 and Type 2 implant placements
Study: 20412501
Drug: Fluoroscopically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopically guided caudal epidural steroid, local anesthetic, and hypertonic saline (group 1)
Study: 20412501
Drug: Fluoroscopically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopically guided caudal epidural steroid, hypertonic saline, local anesthetic, and hyaluronidase (group 2)
Study: 18157412
Drug: Control (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (subcutaneous insulin)
Study: 9042093
Drug: Moderate beer
Normalized name: BEER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate beer consumption (330 mL/day, 20 g of alcohol) for 30 days
Study: 7894522
Drug: BIA in
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA in combination with waist-to-hip ratios
Study: 27534402
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection followed by 12‐h infusion (IV‐IV)
Study: 27534402
Drug: Intracoronary bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary bolus injection followed by intravenous infusion (IC‐IV)
Study: 27534402
Drug: Only intracoronary
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only intracoronary bolus injection (IC)
Study: 27313412
Drug: TC 150
Normalized name: 3TC 150 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC 150 mg
Study: 27313412
Drug: TC 300
Normalized name: 3TC 300 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC 300 mg
Study: 27313412
Drug: TC 150
Normalized name: 3TC 150 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC 150 mg and TC 300 mg
Study: 21289531
Drug: DTwP‐Hib, hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP‐Hib, hepatitis B, and OPV vaccines (Group 2)
Study: 21289531
Drug: DTaP‐IPV‐Hep B‐PRP‐T
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP‐IPV‐Hep B‐PRP‐T with hepatitis B vaccine at birth (Group 3)
Study: 19814699
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg, once daily for 6 weeks
Study: 19814699
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER 4 mg, once daily for 6 weeks
Study: 17057415
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg (subgroup of 6 volunteers)
Study: 15111618
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HD-CT) with cyclophosphamide 1500 mg/m(2), thiotepa 150 mg/m(2), and mitoxantrone 10 mg/m(2) for 4 consecutive days followed by stem-cell support
Study: 15111618
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy (SD-CT) with cyclophosphamide 500 mg/m(2), methotrexate 40 mg/m(2), and fluorouracil 600 mg/m(2) in three cycles
Study: 15111618
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy (SD-CT)
Study: 11692096
Drug: R-albuterol (6.25-1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-albuterol (6.25-1600 microg)
Study: 11692096
Drug: RS-albuterol (12.5-3200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS-albuterol (12.5-3200 microg)
Study: 11692096
Drug: S-albuterol (6.25-1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-albuterol (6.25-1600 microg)
Study: 9204651
Drug: Intravenous clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clodronate (600 mg or 1500 mg in 500 mL of normal saline)
Study: 9204651
Drug: Intravenous clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clodronate
Study: 9204651
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mL of saline)
Study: 9204651
Drug: Blinded choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded choice of agent for pain improvement
Study: 7966073
Drug: Weekly sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly sessions of supervised group physical therapy for a period of 9 months
Study: 3475309
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: professional mechanical tooth‐cleaning, tongue‐scraping, chlorhexidine treatment, and oral hygiene instructions concentrated on the approximal surfaces, treatment given four times with intervals of two days, followed by one single treatment every six months
Study: 3475309
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: same oral hygiene instructions as for Group I, repeated every six months
Study: 3475309
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: preventive program by local Dental Health Office, based on mechanical plaque control and topical use of fluorides and chlorhexidine
Study: 25641556
Drug: Concizumab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concizumab (subcutaneous or intravenous administration)
Study: 16413229
Drug: Investigational treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational treatment
Study: 14616411
Drug: voriconazole +
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: voriconazole + erythromycin (1 g twice daily on days 8-14)
Study: 14616411
Drug: voriconazole +
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: voriconazole + azithromycin (500 mg once daily on days 12-14)
Study: 11414066
Drug: Converting enzyme
Normalized name: Prohormone converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Converting enzyme inhibitor
Study: 7955820
Drug: Simendan (doses:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simendan (doses: 2 mg, 5 mg, 10 mg)
Study: 7955820
Drug: Simendan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simendan (5 mg and 10 mg doses)
Study: 3024863
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral captopril after 1 week of diuretic therapy (50 mg/day furosemide)
Study: 3024863
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day furosemide
Study: 12716240
Drug: Lamotrigine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (titrated from 25 mg/day to 100 mg/day for 6 weeks)
Study: 11055559
Drug: Capsaicin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (2 mg x kg(‐1) ingested 1 hour prior to heat exposure)
Study: 8612382
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate tablet coingested with cimetidine (300 mg)
Study: 8612382
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate solution coingested with cimetidine (300 mg)
Study: 8612382
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate tablet coingested with famotidine (40 mg)
Study: 24604360
Drug: Urea 10%
Normalized name: UREA 10% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea 10% applied to the oral cavity 3-4 times per day for 3 months
Study: 12126242
Drug: Racecadotril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racecadotril (100 mg, three times daily)
Study: 12126242
Drug: Loperamide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (2 mg, three times daily)
Study: 9886591
Drug: Duloxetine (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (exact dosage and duration not specified)
Study: 9226525
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with P:E ratio of 3.2 g/100 kcal
Study: 9226525
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with P:E ratio of 2.6 g/100 kcal
Study: 27107668
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluoxetine and interpersonal psychotherapy adapted to BPD (IPT-BPD)
Study: 27107668
Drug: Single fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single fluoxetine administered for 32 weeks
Study: 22516178
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative intestinal preparation (Control)
Study: 17443678
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (enoxaparin 1 mg/kg per day) and antithrombin (AT) supplementation
Study: 15660024
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of atorvastatin
Study: 15660024
Drug: Higher starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Higher starting doses of atorvastatin
Study: 8644481
Drug: proglumide 1600
Normalized name: proglumide
DrugBank: Proglumide (DB13431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: proglumide 1600 mg
Study: 6987705
Drug: Protamine sulfate
Normalized name: Protamine Sulfate
DrugBank: Protamine (DB13700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protamine sulfate administration post-procedural
Study: 26781645
Drug: Inhalational Ciclesonide
Normalized name: ciclesonide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalational Ciclesonide (CIC) 640 mcg via metered-dose inhaler at admission and 24 hours later
Study: 26781645
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prophylactic therapy)
Study: 26121349
Drug: Esomeprazole (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (2.5-10 mg once daily for 2 weeks, then weight-adjusted doses for 4 weeks)
Study: 23312760
Drug: Low lutein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low lutein (LL; 10 mg/d)
Study: 23312760
Drug: High lutein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High lutein (HL; 20 mg/d)
Study: 23312760
Drug: Lutein plus
Normalized name: Lutein Plus with Zeaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein plus zeaxanthin (LZ; each 10 mg/d)
Study: 18829998
Drug: Verapamil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (1 mg)
Study: 17711714
Drug: CYP1A1 MspI
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP1A1 MspI polymorphism in smokers (CC genotype)
Study: 17711714
Drug: CYP1A1 MspI
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP1A1 MspI polymorphism in low dose cigarette smoking group (CC and TC genotypes)
Study: 17711714
Drug: CYP1A1 MspI
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP1A1 MspI polymorphism in high dose cigarette smoking group
Study: 11473840
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.9% saline
Study: 9517603
Drug: Conservative Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative Therapy (CT)
Study: 525751
Drug: Pyritinol 600
Normalized name: pyritinol
DrugBank: Pyritinol (DB13084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyritinol 600 mg infused immediately after anaesthesia
Study: 30925197
Drug: Daily breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily breakfast (> 700 kcal by 11:00 am)
Study: 24145042
Drug: Clostridial collagenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostridial collagenase ointment (CCO)
Study: 19651562
Drug: Topical pimecrolimus
Normalized name: pimecrolimus Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pimecrolimus 1% cream b.i.d. for 24 weeks
Study: 19651562
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.1% ointment b.i.d. for 24 weeks
Study: 15111848
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - 40 mg of enoxaparin
Study: 15111848
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) - 5000 IU heparin
Study: 8148303
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 20 mL of an amide‐ester solution (1% lidocaine/0.2% tetracaine) with epinephrine 1:200,000
Study: 8148303
Drug: Double injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double injection of two 10 mL injections of the same solution
Study: 2900659
Drug: Steroids for
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids for at least 18 months
Study: 2900659
Drug: Cytotoxic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic agents (27% of patients)
Study: 31315670
Drug: bilateral erector
Approvals — FDA: no, EMA: no, PMDA: no
Description: bilateral erector spinae block (20 mL 0.25% levobupivacaine)
Study: 31315670
Drug: bilateral sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: bilateral sham block (20 mL NaCl 0.9%)